Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Haleon PLC Sponsored ADR ( (HLN) ) has provided an announcement.
On September 9, 2025, Haleon PLC announced the purchase of 1,200,000 ordinary shares for cancellation as part of the second tranche of its share buyback program initiated on July 31, 2025. This move is likely to impact the company’s share capital and voting rights, with the current number of ordinary shares with voting rights standing at 8,952,833,846. The buyback reflects Haleon’s strategic efforts to manage its capital structure and could influence shareholder value positively.
The most recent analyst rating on (HLN) stock is a Hold with a $10.50 price target. To see the full list of analyst forecasts on Haleon PLC Sponsored ADR stock, see the HLN Stock Forecast page.
Spark’s Take on HLN Stock
According to Spark, TipRanks’ AI Analyst, HLN is a Neutral.
Haleon PLC’s overall stock score reflects a strong financial foundation with robust cash flow and profitability margins. However, the lack of revenue growth and challenges in the North American market weigh on the score. Technical indicators and valuation suggest a stable but limited growth outlook, while the earnings call provides some optimism for international performance and operational improvements.
To see Spark’s full report on HLN stock, click here.
More about Haleon PLC Sponsored ADR
Haleon PLC is a global leader in consumer health, focusing on delivering better everyday health with a portfolio that includes Oral Health, Vitamins, Minerals and Supplements, Pain Relief, Respiratory Health, Digestive Health, and Therapeutic Skin Health. The company is known for its trusted brands such as Advil, Centrum, Otrivin, Panadol, parodontax, Polident, Sensodyne, Theraflu, and Voltaren.
Average Trading Volume: 11,309,989
Technical Sentiment Signal: Buy
Current Market Cap: $44.42B
For detailed information about HLN stock, go to TipRanks’ Stock Analysis page.